Arcadia Biosciences, Inc.
RKDA
$3.40
-$0.0813-2.34%
| Weiss Ratings | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.00 | |||
| Price History | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.79% | |||
| 30-Day Total Return | -35.50% | |||
| 60-Day Total Return | -38.54% | |||
| 90-Day Total Return | -21.07% | |||
| Year to Date Total Return | -44.19% | |||
| 1-Year Total Return | 37.61% | |||
| 2-Year Total Return | -60.11% | |||
| 3-Year Total Return | -93.31% | |||
| 5-Year Total Return | -97.35% | |||
| 52-Week High % Change | -66.24% | |||
| 52-Week Low % Change | 88.00% | |||
| Price | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.31 | |||
| 52-Week Low Price | $1.85 | |||
| 52-Week Low Price (Date) | Apr 15, 2024 | |||
| 52-Week High Price (Date) | Dec 05, 2024 | |||
| Valuation | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.75M | |||
| Enterprise Value | -1.62M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.28 | |||
| Earnings Per Share Growth | -76.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.97 | |||
| Price/Book (Q) | 0.46 | |||
| Enterprise Value/Revenue (TTM) | -0.33 | |||
| Price | $3.40 | |||
| Enterprise Value/EBITDA (TTM) | 0.21 | |||
| Enterprise Value/EBIT | 0.21 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.36M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 214 974 8921 | |||
| Address | 5950 Sherry Lane Dallas, TX 75225 | |||
| Website | www.arcadiabio.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -158.89% | |||
| Profit Margin | -119.52% | |||
| Management Effectiveness | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.01% | |||
| Return on Equity | -- | |||
| Income Statement | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.88M | |||
| Total Revenue (TTM) | 4.88M | |||
| Revenue Per Share | $3.57 | |||
| Gross Profit (TTM) | 2.06M | |||
| EBITDA (TTM) | -7.59M | |||
| EBIT (TTM) | -7.75M | |||
| Net Income (TTM) | -5.83M | |||
| Net Income Avl. to Common (TTM) | -5.83M | |||
| Total Revenue Growth (Q YOY) | 18.41% | |||
| Earnings Growth (Q YOY) | -84.98% | |||
| EPS Diluted (TTM) | -4.28 | |||
| EPS Diluted Growth (Q YOY) | 37.40% | |||
| Balance Sheet | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.58M | |||
| Cash Per Share (Q) | $4.82 | |||
| Total Current Assets (Q) | 10.71M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 10.15M | |||
| Current Ratio (Q) | 4.601 | |||
| Book Value Per Share (Q) | $7.54 | |||
| Total Assets (Q) | 15.24M | |||
| Total Current Liabilities (Q) | 2.33M | |||
| Total Debt (Q) | 346.00K | |||
| Total Liabilities (Q) | 5.09M | |||
| Total Common Equity (Q) | 10.29M | |||
| Cash Flow | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 4.88M | |||
| Cash from Financing (TTM) | 9.00K | |||
| Net Change in Cash (TTM) | -6.64M | |||
| Levered Free Cash Flow (TTM) | -310.30K | |||
| Cash from Operations (TTM) | -11.52M | |||
